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Background: Chronic obstructive pulmonary disease (COPD) is a heterogeneous
disease with multiple systemic manifestations and comorbidities, which contribute
independently to its total morbidity and mortality. Pulmonary rehabilitation is an
evidence-based intervention that is indicated for COPD patients who remain
symptomatic, despite optimal pharmacological therapy. Although it is well documented
in pure COPD, the role of pulmonary rehabilitation is uncertain in coexisting
comorbidities. The aim of the present study was to clarify the effect of a pulmonary
rehabilitation program in COPD patients with concomitant comorbidities.
Methods: Thirty two patients with COPD were evaluated before and after a
comprehensive pulmonary rehabilitation program, in terms of dyspnea, quality of life
(QOL), pulmonary function tests and exercise capacity. The patients were also divided
into two groups, according to the presence or the absence of comorbidities. Patients
with none or only one comorbidity (Group 1, n = 11) were compared to those who had
two or more comorbidities (Group 2, n = 21).
Results: All patients significantly improved in dyspnea, as expressed by modified
Medical Research Council scale and the COPD assessment Test (p < 0.001), QOL as
assessed by the St. George respiratory questionnaire (p < 0.001) and exercise tolerance
in six minute walking test (p < 0.001). Peak oxygen uptake relatively increased and body
mass decreased in Group 1 compared to Group 2 (p < 0.05).
Conclusion: Pulmonary rehabilitation in COPD seems to be beneficial for all patients,
independently of the presence, the number or the nature of their comorbidities. Thus,
the presence of comorbidities must not represent an exclusion criterion for patients that
are referred to pulmonary rehabilitation programs.
Trial Registration: Current controlled trials ISRCTN14648515 Retrospectively
registered 15 February 2018.
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INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is a progressive
disease associated with significant morbidity and mortality. The
latest Global Initiative for Obstructive Lung Disease (GOLD)
defines the disease as: “A common preventable and treatable
disease, characterized by persistent airflow limitation that is
usually progressive and associated with an enhanced chronic
inflammatory response in the airways and the lung to noxious
particles or gases. Exacerbations and comorbidities contribute
to the overall severity in individual patients” (Global strategy
for the diagnosis, management and prevention of COPD, global
initiative for chronic obstructive lung disease (GOLD), 2016).
Several studies demonstrate that 86–98% of COPD patients
have at least one comorbidity, with the average number per
individual varying between from 1.2 to 4.0 (Putcha et al., 2013,
2015). Comorbidities often contribute to dyspnea, limitation of
exercise capacity, deterioration of quality of life (QOL), increased
healthcare utilization and cost, and increased exacerbation and
mortality risk (Patel and Hurst, 2011). COPD patients are more
likely to die from a comorbid disease than COPD itself, as “only
40% of the deaths are definitely or probably related to COPD,
with the remainder being mostly unrelated to COPD (50%) or
unknown (9%)” (McGarvey et al., 2007). Based on this evidence,
current guidelines for the management of COPD, besides treating
chronic airflow limitation with traditional pharmacological
therapy, adopt a more holistic approach by incorporating the
assessment and appropriate treatment of comorbid diseases in
order to ameliorate the health status and the prognosis of the
patients (GOLD Global strategy for the diagnosis, management
and prevention of COPD, global initiative for chronic obstructive
lung disease (GOLD), 2016).
Common comorbidities in patients with COPD include
cardiovascular disease (CVD) (such as arterial hypertension,
systemic venous thromboembolism (VTE), stroke, heart failure,
coronary heart disease, arrhythmias and pulmonary hyperten-
sion), lung cancer and other cancers, psychiatric diseases (such
as anxiety and depression disorders), metabolic conditions (such
as malnutrition, obesity, diabetes mellitus, dyslipidemia), anemia,
osteoporosis, musculoskeletal dysfunction, sleep disorders and
gastroesophageal reflux (Patel and Hurst, 2011). Some of these
comorbidities (pulmonary artery disease and malnutrition)
are directly caused by COPD (secondary to COPD), whereas
others share common risk factors, such as lifestyle factors
(e.g., smoking), environmental exposures (place of work, air
pollution etc.), and genetic susceptibility, and are associated with
similar pathophysiological mechanisms, like airway and systemic
inflammation, lung hyperinflation and endothelial dysfunction
and oxidative stress (Patel and Hurst, 2011).
Pulmonary rehabilitation is an evidence-based inter-
vention that is indicated for COPD patients who remain
Abbreviations: 6MWT, six minute walking test; ATS, American Thoracic Society;
BMI, body mass index; CAT, COPD assessment test; COPD, chronic obstructive
pulmonary disease; CPR, cardiopulmonary resuscitation; CVD, cardiovascular
disease; GOLD, global initiative for obstructive lung disease; MRC, medical
research council; QOL, quality of life; SGRQ, St. George respiratory questionnaire;
VO2peak, Peak oxygen uptake; VTE, systemic venous thromboembolism.
symptomatic – despite optimal pharmacological therapy – to
reduce dyspnea, increase exercise capacity and improve QOL
(Spruit et al., 2013). Exercise training is the best available
way of improving muscle function and exercise tolerance
in patients with COPD (Wu et al., 2017). Moreover, regular
physical activity is recommended and is beneficial for patients
with CVD, musculoskeletal disease, obesity, diabetes mellitus
and most other chronic medical conditions (Ciolac, 2013).
However, a review on this topic concluded inconsistent data
about pulmonary rehabilitation outcomes in COPD patients
with comorbidities (Franssen and Rochester, 2014). For instance,
patients with multiple comorbidities would present limited
benefits from their participation in pulmonary rehabilitation
(Crisafulli et al., 2008), whereas most comorbidities were not
related to rehabilitation outcomes (Crisafulli et al., 2010). In most
studies reported in the abovementioned review, outcomes were
evaluated with functional exercise capacity as measured by six
minute walking test (6MWT) and not with peak oxygen uptake
(VO2peak) as measured during incremental exercise. Some
studies proved worse outcomes in patients with cardiovascular,
metabolic or psychological comorbid conditions, whereas others
did not confirm this or reported opposite effects (Franssen and
Rochester, 2014). Such knowledge would be of great practical
value for practitioners working with COPD as it would allow
them prescribing optimal pulmonary rehabilitation programs.
Therefore, the aim of our study was to further clarify
pulmonary rehabilitation outcomes in stable COPD patients with
coexisting comorbidities, in terms of specific diseases and total
number. The principal end points were QOL, degree of dyspnea
and aerobic capacity. We assessed exercise capacity using both
6MWT and VO2peak, in order to evaluate possible differences in
results between the two methods.
MATERIALS AND METHODS
Thirty two patients with COPD (25 men and 7 women, age
66 ± 6 years, body mass index (BMI) 27.14 ± 4.88 kg/m2)
(Table 1), sample of convenience, were selected for the present
study from our outpatient clinics in the Division of Pulmonology,
to the Department of Clinical Therapeutics of the National
and Kapodistrian University of Athens School of Medicine, at
Alexandra Hospital of Athens. COPD was diagnosed by history,
physical examination, and standard pulmonary function tests
according to GOLD criteria (Global strategy for the diagnosis,
management and prevention of COPD, global initiative for
chronic obstructive lung disease (GOLD), 2016). Also, at baseline
each patient underwent detailed general medical history –
including the number, the type and the medications of other
coexisting diseases. Finally, each patient signed a written
informed consent and the study protocol was approved by the
Ethical Committee of our hospital. The study adheres to the
CONSORT criteria (Figure 1). All data are available in the
Supplementary Material.
Eligible participants were 25 men and 7 women, with mean age
66 ± 6 years-old (range: 49–76) who met the following inclusion
criteria: (1) COPD diagnosis of any stage (A, B, C, D), (2) stable
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TABLE 1 | Baseline characteristics of participants.
Parameters Total (n = 32) Group 1 (n = 11) Group 2 (n = 21)
Patients (number
(%), males/females)
25 (78%)/7 (22%) 10 (91%)/1 (9%) 15 (71%)/6 (29%)
Age (years) 66.03 ± 6.03 64.36 ± 5.45 66.91 ± 6.26
BMI (kg/m2) 27.14 ± 4.88 25.36 ± 4.73 28.07 ± 4.81
FEV1 (L) 1.297 ± 0.605 1.09 ± 0.53 1.40 ± 0.63
FEV1 (% predicted) 43.08 ± 15.07 35.78 ± 14.12 48.02 ± 15.16∗
FEV1/FVC (%) 51.67 ± 10.25 45.43 ± 6.93 54.94 ± 10.30∗
RV/TLC (%) 54.87 ± 19.68 68.20 ± 28.98 47.76 ± 5.73∗
TLCO (% predicted) 38.2 ± 22.8 21.7 ± 18.0 61.8 ± 20.0∗
MRC 2.5 ± 0.9 2.5 ± 1.0 2.5 ± 0.9
CAT 16.9 ± 9.3 15.6 ± 5.7 17.5 ± 10.8
SGRQ 47.3 ± 19.0 41.1 ± 16.2 50.5 ± 20.0
GOLD Severity
(number, A/B/C/D)
1/9/14/8 0/2/4/5 1/7/10/3
6MWT (m) 280 ± 81 297 ± 95 271 ± 74
Workload (W) 58.4 ± 31.5 56.1 ± 29.6 59.5 ± 33.1
VO2peak
(mL min−1 kg−1)
13.2 ± 4.1 16.9 ± 5.0 11.9 ± 3.7∗
BMI: Body Mass Index, FEV1: Forced Expiratory Volume in 1 s, FVC: Forced
Vital Capacity, RV: Residual Volume, TLC: Total Lung Capacity, TLCO: Diffusing
Capacity, MRC: modified Medical Research Council scale, CAT: COPD Assessment
Test, SGRQ: St. George Respiratory Questionnaire, GOLD: Global Strategy for the
diagnosis, management, and prevention of COPD, 6MWT: 6 min Walking Test,
VO2peak: Peak Oxygen Uptake. ∗p < 0.05.
condition, (3) optimal bronchodilation therapy, (4) optimal
therapy of comorbidities, (5) reduced exercise capacity, and
(6) completed successfully all parts of experimental intervention.
Stable COPD was defined as no history of exacerbation in last
2 months prior to the study (Biswas et al., 2017).
The patient population was divided in two groups,
according to the presence or the absence of comorbidities.
The comorbidities were both self-reported and confirmed in
the medical records of the patients. Patients with none or
only one comorbidity (n = 11, Group 1) were compared to
those who had two or more comorbidities (n = 21, Group 2),
in terms of dyspnea, QOL and exercise capacity, before and
after a pulmonary rehabilitation program. The characteristics
of each group were presented in Table 1. The experimental
intervention was administered twice a week, for 13 weeks
between 1 November 2012 and 31 December 2014 at the Division
of Pulmonology, Department of Clinical Therapeutics of the
National and Kapodistrian University of Athens School of
Medicine, at Alexandra Hospital of Athens. Comorbidities were
assessed using patient-report of a physician diagnosis.
At baseline, each patient underwent clinical examination,
arterial blood gases analysis (GEM Premier 3500, United States),
and Pulmonary Function Tests (PFTs) (Master screen Diffusion,
Jaeger, Germany): spirometry (pre/post-bronchodilation),
diffusing capacity and static lung volumes. Dyspnea was assessed
by both the modified Medical Research Council (MRC) scale
(Simsic et al., 2018) and the COPD Assessment Test (CAT)
(Jo et al., 2018). QOL was assessed by the St. George Respiratory
Questionnaire (SGRQ) (Oliveira and Marques, 2017). BMI was
calculated using patient’s weight in kilograms (kg) divided by his
or her height in meters squared.
Six minute walking test (Reychler et al., 2016) and standard
cardiopulmonary exercise test (Ergoline Variable 500, Viasys
Health Care, Jaeger, Germany) were also carried out, while
breathing room air. Expiratory oxygen and carbon dioxide
fractions, work rate, airflow, cardiac frequency and oxygen
saturation were continuously recorded. The results were obtained
(1) at rest, (2) after 1 min of unloaded exercise, and (3) during
incremental exercise. The incrementation rate was 25 W per
minute. The pedaling frequency was constant at 60 revolutions
per min. Each patient exercised against progressive workloads up
to symptom-limited, maximum exercise capacity. All indications
to stop the test were known by the personnel involved in the
testing. The procedure was performed under the supervision of
a physician trained in conducting exercise tests and in advanced
cardiopulmonary resuscitation (CPR). Full CPR equipment was
available in the laboratory.
After the initial assessment, each patient started an indivi-
dualized rehabilitation program, at the Pulmonary Rehabilitation
Department of Sotiria Hospital, twice a week, for a period of
13 weeks (Table 2). The program included (1) interval, endurance
exercise training using cycle ergometer to 100% of WRmax of
each patient, switching between exercise and rest, for 40 min,
(2) continuous endurance exercise training using treadmill
for 10–20 min, (3) lower and upper extremity strengthening
exercise training-conditioning using mainly weight lifting for
5–15 sets, (4) breathing retraining (pursed lips breathing
technique) and (5) respiratory muscle training. Education,
diet and psychological support were provided by specialized
personnel during the experimental period. Other important
therapeutic modalities that were stressed during the program
included smoking cessation, oxygen therapy, and use of
bronchodilators and antibiotics. At the end of the 13 weeks
period of training, the patients were reassessed using the same
testing protocol.
The values of all functional parameters were expressed as
mean and standard deviation (M ± SD). An independent t-test
examined differences between the two experimental groups.
A between-within subjects analysis of variance examined the
main effect of time and the time × group interaction on
QOL, dyspnea and exercise tolerance. The magnitude of the
differences between experimental groups was examined using
effect size eta square (η2) and was evaluated as following: small
(0.010 < η2 ≤ 0.059), moderate (0.059 < η2 ≤ 0.138) and large
(η2 > 0.138) (Cohen, 1988). The correlations among the pre-post
changes in exercise tolerance, dyspnea or QOL, and the baseline
COPD stage were examined using the Spearman correlation
coefficient rho. The acceptable type I error was set at p< 0.05.
RESULTS
The presence of comorbidities was very common (n = 28,
87.5% of patients) and included cardiovascular, diabetes mellitus,
osteoporosis, psychological, and sleep disorders and cancers
(Table 3). The two more frequently observed comorbidities
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FIGURE 1 | CONSORT flow graph showing the enrollment, allocation, follow-up and analysis of participants.
were CVD and diabetes mellitus (n = 22, 68.8% and n = 17,
53.1%, respectively).
No statistically significant differences in performing the
program were observed between the two groups. A large main
effect of time was observed in MRC (p < 0.001, η2 = 0.665),
CAT (p < 0.001, η2 = 0.621), SGRQ (p < 0.001, η2 = 0.457),
which decreased, and in 6MWT (p < 0.001, η2 = 0.608),
which increased across time (Figures 2, 3). No main effect
of time was shown in body mass (p = 0.313, η2 = 0.035),
BMI (p = 0.251, η2 = 0.045), FEV1 (p = 0.626, η2 = 0.009)
and VO2peak (p = 0.074, η2 = 0.159). A large time ∗ group
interaction was found in body mass (p = 0.012, η2 = 0.198)
with decrease in group 1 compared to group 2 and VO2peak
(p = 0.025, η2 = 0.238) with increase in group 1 compared
to group 2. No time ∗ group interaction was observed in
BMI (p = 0.249, η2 = 0.046), MRC (p = 0.859, η2 = 0.001),
CAT (p = 0.279, η2 = 0.039), SGRQ (p = 0.983, η2 < 0.001),
6MWT (p = 0.888, η2 = 0.001) and FEV1 (p = 0.783, η2 = 0.003).
In summary, the indices of dyspnea (MRC and CAT), QOL
(SGRQ) and aerobic capacity (6MWT) improved across time.
The combined effect of group and time was shown only in body
mass and VO2peak.
The severity of the disease was not significantly associated
with any of the observed changes after the rehabilitation program
(rho ≤ 0.23, p ≥ 0.205). Only the reduction of dyspnea tended to
be less – but not statistically significant – in severe and very severe
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TABLE 2 | Characteristics of pulmonary rehabilitation program.
General approach The program was multimodal and evolutionary for
each participant.
Overall sessions Twenty-five sessions for each participant.
Content Each session consisted by both physical therapy
modalities for the respiratory system and exercise.
Exercise included both aerobic (treadmill, cycle
ergometer and arm crank ergometer) and resistance
training (3 set × 10–15 repetitions for 6–8 exercises of
main muscle groups). Oxygen supply was provided
continuously to maximize effort and exercise intensity
maintaining hemoglobin saturation higher than 90%.
Physical therapy included relaxation techniques for
dyspnea, pursed lips breathing technique, exercise of
diaphragm/respiratory muscles and effective cough.
Personnel Participants were instructed by physical therapists
under the guidance of physician and nurse.
Frequency Two sessions weekly (Monday and Thursday
morning). The participants were encouraged and
guided to perform an additional session by their own.
Exercise intensity Dyspnea was continuously monitored during each
session using Borg scale and was considered to
regulate exercise intensity.
TABLE 3 | Prevalence of selected comorbidities in participants.
Comorbidity Frequency (n) Percentage (%)
Cardiovascular 22 68.8
Diabetes mellitus 17 53.1
Sleep apnoea and other lung diseases 5 15.6
Osteoporosis 4 12.5
Lung cancer 1 3.1
Other cancers 5 15.6
Psychiatric 3 9.4
Chronic kidney failure 1 3.1
Gastrointestinal reflux 0 0
COPD patients when compared to mild and moderate COPD
patients (DMRC: 33% vs. 50%).
VO2peak showed a significant percentage increase of 25.7%
in the subgroup of patients with none or one comorbidity
(Group 1) compared to the subgroup of patients with two or
more comorbidities (Group 2). However, the total number or/and
specific comorbidities (CVD and diabetes mellitus) were not
related to the general outcomes of pulmonary rehabilitation
program, according to the correlation analysis. No harm was
observed in participants.
DISCUSSION
Our prospective study demonstrated that all COPD patients
improved, after a 13 week pulmonary rehabilitation program,
in terms of dyspnea (MRC and CAT), QOL (SGRQ) and
exercise tolerance in 6MWT, independently of the presence, the
number or the nature of their comorbidities. We did not observe
significant responses in FEV1 or VO2peak. To the best of our
knowledge, this is the first study that evaluates the results of a
rehabilitation program by both 6MWT and CPET.
It is well documented that pulmonary rehabilitation reduces
dyspnea, improves QOL and increases exercise capacity in
COPD patients (Spruit et al., 2013), especially in those who
remain symptomatic despite maximal pharmacological therapy.
Although COPD is characterized by multi – morbidity, which
leads to worse disease symptoms, increased health care utilization
and significant mortality, available data about the effect of
comorbidities on pulmonary rehabilitation outcomes in COPD
still conflicting (Crisafulli et al., 2008, 2010; Franssen and
Rochester, 2014).
Most previous studies, that reported worse response
after rehabilitation, in COPD patients with co-existing
cardiovascular or metabolic diseases, were retrospective
FIGURE 2 | The effect of pulmonary rehabilitation on dyspnea, quality of life (QOL) and aerobic capacity. Group 1 = patients with none or only one comorbidity,
Group 2 = patients with two or more comorbidities, BMI = body mass index, FEV1 = forced expiratory volume in 1 s, MRC = modified Medical Research Council
scale, CAT = COPD assessment test, SGRQ = St. George respiratory questionnaire, GOLD = global strategy for the diagnosis, management, and prevention of
COPD, 6MWT = 6 min walking test, VO2peak = peak oxygen uptake. ∗group × time interaction at p < 0.05, #main effect of time at p < 0.05.
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FIGURE 3 | Inter-individual variability in changes of dyspnea, QOL and aerobic capacity following pulmonary rehabilitation. BMI = body mass index, FEV1 = forced
expiratory volume in 1 s, MRC = modified Medical Research Council scale, CAT = COPD assessment test, SGRQ = St. George respiratory questionnaire,
GOLD = global strategy for the diagnosis, management, and prevention of COPD, 6MWT = 6min walking test, VO2peak = peak oxygen uptake.
(Crisafulli et al., 2008; Vagaggini et al., 2009; Carreiro
et al., 2013). In some studies, health status and/or 6MWT
were negatively influenced by the presence of cardiac or
metabolic diseases (Crisafulli et al., 2008; Vagaggini et al.,
2009; Carreiro et al., 2013). On the contrary, another
retrospective study, reported better response in 6MWT
in COPD patients with metabolic diseases (Walsh et al.,
2013). BMI > 25 kg m−2 was an independent predictor
of improvement in 6MWT, but not in SGRQ, in one study
(Vagaggini et al., 2009), whereas other studies did not
observe any difference between obese and non-obese patients
(Ramachandran et al., 2008; Greening et al., 2012). Psychological
symptoms led to reduced improvement in dyspnea (Carreiro
et al., 2013) and increased risk of drop-out of the program
(Garrod et al., 2006).
Our study was prospective and our data were in partial
accordance with previous studies. All COPD patients,
independently of the number or the nature of comorbidities,
achieved less dyspnea and better QOL after the rehabilitation
program. The level of dyspnea was higher and tended to
ameliorate less – but not statistically significant – in severe and
very severe COPD patients, compared to moderate and mild
patients. Probably more severe patients have more dyspnea
and a significant degree remains even after the intervention.
Cardiovascular or metabolic comorbidities were not associated
with the outcomes of the rehabilitation program.
The objective performance of participants was measured
by both 6MWT and CPET. All patients improved in 6MWT,
but not in workload or VO2peak. In previous studies the
most commonly assessed test was the 6MWT. It is reliable,
simple, and of low cost. Furthermore, 6MWT resembles
daily activities, as patients use to walk and not to cycle.
However, changes in the 6MWT are not significantly correlated
to changes in other indices of exercise performance (Ong
et al., 2004), as it only measures a narrow range of the
physical performance spectrum. Also, the 6MWT appears to
be less sensitive to intervention than the CPET (Fotheringham
et al., 2015). Group 1 achieved significantly better VO2peak
compared to Group 2, after the rehabilitation program. This
was in accordance with a previous study which showed that
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the improvement in exercise capacity was significantly greater
in patients without significant comorbidities (Crisafulli et al.,
2008).Probably patients with better baseline condition have
greater possibility for improvement.
The amelioration of symptoms and exercise capacity,
as expressed by 6MWT, in the whole population – independently
of coexisting comorbidities – can be explained by the fact
that physical activity and regular exercise are beneficial not
only for patients with COPD, but also for patients with CVD,
musculoskeletal disease, obesity, diabetes mellitus and most other
chronic medical conditions (Franssen and Rochester, 2014).
Moreover, in patients with heart failure or diabetes mellitus
type 2, prescribed exercise, involving aerobic and resistance
training modalities, is also evidence-based treatment (McMurray
et al., 2012). Thus, pulmonary rehabilitation is beneficial for
individuals with COPD and comorbidities, as it has positive
effects on both.
The major limitation of our study is the small number
of the patients. Besides, the severity of their comorbidities
is not quantified and we considered only the number of
presented comorbidities (i.e., none or one versus two to
nine). Also, a major point of discussion is whether the
results suggest real pathophysiologic differences in the
response to pulmonary rehabilitation or are due to a greater
deconditioning in chronic illness patients. On the other
hand, strength of the study was its novelty as limited
information existed so far about the role of the number of
comorbidities on the effectiveness of a rehabilitation program
for COPD (Negewo et al., 2015). Considering the high
prevalence of COPD (Sobrino et al., 2017) and the key role
of comorbidities (Koskela et al., 2014), the findings of the
present study were of great practical importance for practitioners
working with COPD.
CONCLUSION
We conclude that all COPD patients benefit from a pulmonary
rehabilitation program, independently of comorbidities. More
severe patients and patients with ≥2 comorbidities have inferior
outcomes when compared to moderate or to patients with
0–1 comorbidity. More studies are required to evaluate the
effects of this intervention in the natural history of COPD
and comorbidities.
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